Profile: Acorda Therapeutics Inc (ACOR.O)
Acorda Therapeutics, Inc., incorporated on March 17, 1995, is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS.
The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa (L-dopa). As of December 31, 2016, CVT-301 was in Phase III development for the treatment of OFF periods in people with Parkinson's disease. Ampyra is an extended release tablet formulation of dalfampridine (4-aminopyridine, 4-AP). Ampyra is marketed as Fampyra outside the United States. The Company is engaged in developing CVT-427, an inhaled triptan (zolmitriptan) intended for acute treatment of migraine. The Company holds the rights to tozadenant, an oral adenosine A2a receptor antagonist in Phase III development as an adjunctive treatment to levodopa in Parkinson's disease patients to reduce OFF time. The Company holds the global rights to SYN120, an oral, 5-hydroxytryptamine (HT)6/5-HT2A dual receptor antagonist in Phase II development for Parkinson's-related dementia. The Company's subsidiary, Biotie Therapies Corp., is developing BTT1023 (timolumab), a product candidate for the orphan disease Primary Sclerosing Cholangitis (PSC), a chronic and progressive liver disease.
The Company is developing rHIgM22, a remyelinating antibody, as a therapeutic for MS. Cimaglermin alfa is its lead product candidate for its neuregulin program. As of December 31, 2016, the Company had conducted a Phase I clinical trial of Cimaglermin alfa in heart failure patients. The Company's commercial products include Selincro for alcohol dependence. The Company's research and development programs include the Chondroitinase Program for spinal cord injury.
The Company competes with Bayer AG, Teva Pharmaceutical Industries, Ltd., Merck Serono, Novartis AG, Sanofi, Biogen International GmbH, AbbieVie and F. Hoffman-La Roche AG.
Acorda Therapeutics Inc
420 Saw Mill River Rd
ARDSLEY NY 10502-2605
Company Web Links
- BRIEF-Acorda Therapeutics, in May 2017, filed planned appeal of decision on 4 invalidated patents with U.S. court of appeals for federal circuit
- BRIEF-Acorda Therapeutics says expects results from Tozadenant phase 3 clinical trial in Q1 2018
- BRIEF-CVT-301 phase 3 data showed significantly positive results
- BRIEF-Acorda Therapeutics plans to file NDA for Inbrija with U.S. FDA by end of Q2
- BRIEF-Acorda qtrly GAAP net loss $0.41 per diluted share